Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jan Emmerich
Observed name:
J. Emmerich
Institution:
Synthekine
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
Research Institute of Molecular Pathology,
Synthekine,
Institut für Immunologie,
University of Bayreuth,
Ludwig-Maximilians-Universität München
show all 6
ORCID:
0000-0002-7216-2231
Observed ORCID:
0000-0002-7216-2231
OpenAlex ID:
A5012168959
Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells
2007
·
Katharina Aschenbrenner
, Louise M D'Cruz
, et al.
·
Nature Immunology
·
610
Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance
2008
·
Jelena Nedjic
, Martin Aichinger
, et al.
·
Nature
·
552
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
2011
·
John B. Mumm
, Jan Emmerich
, et al.
·
Cancer Cell
·
433
PDF
IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
2012
·
Jan Emmerich
, John B. Mumm
, et al.
·
Cancer Research
·
279
IL-2 based cancer immunotherapies: an evolving paradigm
2024
·
Sushama Rokade
, Anita Mehta Damani
, et al.
·
Frontiers in Immunology
·
88
An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma
2021
·
Paul-Joseph Aspuria
, Sandro Vivona
, et al.
·
Science Translational Medicine
·
86
Cyclin D Does Not Provide Essential Cdk4-Independent Functions in Drosophila
2004
·
Jan Emmerich
, Claas A Meyer
, et al.
·
Genetics
·
35
Drosophilap27Dacapo expression during embryogenesis is controlled by a complex regulatory region independent of cell cycle progression
2002
·
Claas A. Meyer
, Ina Kramer
, et al.
·
Development
·
32
Abstract 1744: STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor
2021
·
Jan Emmerich
, Michele Bauer
, et al.
·
Cancer Research
·
17
Selection and Behavior of CD4+ CD25+ T Cells In Vivo: Lessons from T Cell Receptor Transgenic Models
2005
·
L. Klein
, J. Emmerich
, et al.
·
Current topics in microbiology and immunology
·
8
Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8+T cells
2012
·
Jan Emmerich
, John B. Mumm
, et al.
·
OncoImmunology
·
7
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy
2025
·
Ievgen Koliesnik
, Michael Totagrande
, et al.
·
Cell Reports
·
5
OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy
2020
·
Paul-Joseph Aspuria
, Michael A Bauer
, et al.
·
Blood
·
2
1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window
2023
·
Zhenya Koliesnik
, Michael Totagrande
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity
2023
·
Martin Oft
, Navneet Ratti
, et al.
·
Cancer Research
·
1
Abstract 1833: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity
2023
·
Ievgen Koliesnik
, Jan Emmerich
, et al.
·
Cancer Research
·
1
1041 Preferential stimulation of antigen activated CD25 + CD8 T cells with STK-012, an α/β biased IL-2, avoids capillary leak syndrome and enhances anti-tumor immunity
2026
·
In-Young E Jung
, Jan Emmerich
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
964 Gradual lymphocyte activation with IL-12 partial agonist STK-026 maintains anti-tumor efficacy but escapes acute NK-mediated cytokine release and toxicities associated with WT IL-12
2024
·
Zhenya Koliesnik
, Michael Totagrande
, et al.
·
Journal for ImmunoTherapy of Cancer
Supplementary Figures 1-3 from IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
2023
·
Jan Emmerich
, John B. Mumm
, et al.
Data from IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
2023
·
Jan Emmerich
, John B. Mumm
, et al.
Data from IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
2023
·
Jan Emmerich
, John B. Mumm
, et al.
Abstract 586: Orthogonal IL-2/IL-2RB signaling in adoptively transferred T cells controls tumor growth without the need for lymphodepletion in a B16 tumor model
2022
·
Christina Kochel
, Meng Sun
, et al.
·
Cancer Research
Abstract 1512: OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumor efficacy by driving T cell expansion and fitness
2021
·
Paul-Joseph P. Aspuria
, Sandro Vivona
, et al.
·
Cancer Research
Abstract 3252: OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficacy and durability of response
2020
·
Paul-Joseph Aspuria
, Michele Bauer
, et al.
·
Cancer Research
Killing from within
2012
·
John B. Mumm
, Jan Emmerich
, et al.
·
OncoImmunology
Show more works
View as search
Works count:
25
Citation count:
2,157
H-index:
9
I10-index:
9
Year
Topic
Type
